All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ISD-017
Therapeutic Area: Immunology Product Name: ISD-017
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Biogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 23, 2020
Details:
ISD and Biogen will work together to develop ISD's lead compound, ISD 017, which is being developed to treat severe lupus - systemic lupus erythematosus (SLE).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HT-005 Z-PODS
Therapeutic Area: Immunology Product Name: HT-005
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Zylo Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
Details:
The animal study supports that HT-005 has the potential to be an effective treatment for cutaneous manifestations of lupus, a significant unmet medical need.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OSE-230
Therapeutic Area: Immunology Product Name: OSE-230
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2020
Details:
The poster presentation highlights efficacy results for OSE-230 in chronic inflammatory preclinical models and ex vivo human models.inflammatory preclinical models and ex vivo human models.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PT001
Therapeutic Area: Immunology Product Name: PT001
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
Pandion utilizes its TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform to create antibody-based candidates that target known control nodes in the immune system.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hydroxyl dendrimer
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
In a preclinical study, systemically administered HDs localized to sites of inflammation in arthritic tissues. When alendronate, which binds bone, was conjugated to the HD, the HD was targeted to the bone with less uptake in reactive macrophages away from the bone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMP761
Therapeutic Area: Immunology Product Name: IMP761
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
The claims of the patent are directed to Immutep’s pre-clinical product candidate, IMP761, and also to the use of IMP761 in the treatment of T-cell mediated inflammatory and autoimmune diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Piroxicam
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Quotient Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
In the clinical trial, Nanoform will investigate the behavior of an oral immediate release (IR) nanoformed formulation of piroxicam, an anti-inflammatory drug.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pegadricase,IgA proteases
Therapeutic Area: Immunology Product Name: SEL-212
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Selecta Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 08, 2020
Details:
The companies have entered into a Research License and Option agreement to study Selecta’s ImmTOR™ immune tolerance platform in combination with IGAN’s immunoglobulin A (IgA) protease for the treatment of IgA Nephropathy (IgAN).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ImmCelz
Therapeutic Area: Immunology Product Name: ImmCelz
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
ImmCelz® utilizes adult stem cells derived from qualified donors, to endow specific properties to patient immune cells. Creative Medical Technology conducted studies showed efficacy of its ImmCelz® immunotherapy product in the collage induced model of rheumatoid arthritis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CEL-4000
Therapeutic Area: Immunology Product Name: CEL-4000
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
CEL-SCI’s LEAPS technology relates to peptide constructs which may be useful in the treatment or prevention of autoimmune diseases, particularly rheumatoid arthritis, asthma, allergies, and host versus graft (or graft versus host) rejection.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
